Abstract
We report an interesting case of acute myelogenous leukemia (AML) in a Jehovah’s Witness patient. A 61-year-old woman, a Jehovah’s Witness, consulted our hospital because of continuous fever and refractory pharyngitis. The white blood cell count was increased with myeloblasts and monoblasts, both of which showed positivity for CD33.The level of WT1 messenger RNA (mRNA) in the bone marrow was 130,000 copies/μg RNA. The patient’s diagnosis was AML (M4). Because complete remission (CR) was not obtained with 2 courses of chemotherapy consisting of acrarubicin and cytarabine, we tried gemtuzumab ozogamicin (GO) with informed consent. No major side effects appeared, and CR was obtained after 2 courses of GO, which decreased the WT1 mRNA level to 480 copies/μg RNA. The patient has been in CR for 6 months with ubenimex. This case suggests that GO can be one of the treatment options in similar situations, although it should be used with considerable care.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Giles F, Estey E, O’Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer. 2003;98:2095–2104.
Sperr WR, Florian S, Hauswirth AW, Valent P. CD33 as a target of therapy in acute myeloid leukemia: current status and future. Leuk Lymphoma. 2005;46:1115–1120.
Cullis JO, Duncombe AS, Dudley JM, Lumley HS, Apperley JF, Smith AG. Acute leukaemia in Jehovah’s Witnesses. Br J Haematol. 1998;100:664–668.
Laszlo D, Agazzi A, Goldhirsch A, et al. Tailored therapy of adult acute leukemia in Jehovah’s Witnesses: unjustified reluctance to treat. Eur J Haematol. 2004;72:264–267.
Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH. Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah’s Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. Am J Hematol. 1996;51:251–252.
Fujita H, Maruta A, Koharazawa H, et al. Successful treatment of a Jehovah’s Witness with acute promyelocytic leukemia. Int J Hematol. 1997;65:415–416.
Menendez A, Svarch E, Martinez G, Hernandez P. Successful treatment of acute promyelocytic leukemia using all-trans retinoic acid and erythropoietin in a Jehovah’s Witness boy. Ann Hematol. 1998;76:43–44.
Kennedy GA, Marlton P, Cobcroft R, Gill D. Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah’s Witness with de novo acute promyelocytic leukaemia. Br J Haematol. 2000;111:1103–1105.
Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005;19:176–182.
Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med. 2000;247:521–534.
Motoji T, Motomura S, Wang YH. Multidrug resistance of acute leukemia and a strategy to overcome it. Int J Hematol. 2000;72:418–424.
Bareford D, Odeh B, Narayanan S, Wiltshire S. Remission induction in a Jehovah’s Witness patient with acute myeloid leukemia using gemtuzumab ozogamicin. Transfusion Med. 2005;15:445–448.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Fujisawa, S., Naito, K., Matsuoka, T. et al. Complete Remission Induced by Gemtuzumab Ozogamicin in a Jehovah’s Witness Patient with Acute Myelogenous Leukemia. Int J Hematol 85, 418–420 (2007). https://doi.org/10.1532/IJH97.07018
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.07018